Genentech Drops Actimmune For Renal Cell Carcinoma
Genentech has decided to discontinue the development of its Actimmune (interferon gamma-1b) product as a treatment for renal cell carcinoma, following lackluster results from its Phase III trials of the drug.
Data have now been analyzed from Genentech's two Phase III trials of the drug. The first was an open-label, non-randomized US study while the second was a randomized, double-blind placebo-controlled Canadian study. The response rate to Actimmune was about the same in both studies, and the placebo-controlled study found no statistically-significant difference in response rate, response duration, time to progression or survival between the active and control groups.
Actimmune is marketed for the treatment of chronic granulomatous disease in the USA. Genentech was also conducting these studies on behalf of Boehringer Ingelheim, which has European rights to the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze